Blar i Institutt for klinisk og molekylær medisin på tittel
Viser treff 2802-2821 av 3426
-
SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway
(Peer reviewed; Journal article, 2022)Objectives: To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals ... -
SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells
(Peer reviewed; Journal article, 2022)Natural killer (NK) cells are innate immune cells that contribute to host defense against virus infections. NK cells respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and are activated in ... -
Saving β-Cells from Demise:Effects of in vitro Conditions and Genetic Engineering of UCP-2
(Doktoravhandlinger ved NTNU, 1503-8181; 2014:106, Doctoral thesis, 2014)Motverking av skade på β-celler: effekt av endra in vitro-forhold og genetisk manipulering av UCP-2 Beta (β)-cellene, som produserer insulin, ligg samla i såkalla Langerhanske (L) øyer i bukspyttkjertelen. Ved diabetes er ... -
School grades and educational attainments of adolescents and young adults born preterm
(Peer reviewed; Journal article, 2023)Attendance in special education (SE) is more common among individuals born preterm than among those born at term. Less is known about school grades of those born preterm in mainstream education (ME), and how these grades ... -
School wellbeing among children in grades 1-10
(Journal article; Peer reviewed, 2010)Background: Determinants of children’s school wellbeing have not been extensively studied. In this cross-sectional study of school children we assessed how factors assumed to promote wellbeing and factors assumed to ... -
Scientific knowledge in the age of computation: Explicated, computable and manageable?
(Journal article; Peer reviewed, 2019)With increasing publication and data production, scientific knowledge stands not simply as an achievement but also as a challenge. Scientific publications and data are increasingly treated as resources that need to be ... -
Scientific Opinion on a notification (reference C/NL/09/01) for the placing on the market of the genetically modified carnation IFD-25958-3 with a modified colour, for import of cut flowers for ornamental use, under Part C of Directive 2001/18/EC from Florigene
(Journal article, 2014)Genetically modified (GM) carnation IFD-25958-3 was developed to express anthocyanins in the petals conferring a mauve colour to the flowers. The GM carnation is intended to be imported in the European Union as cut flower ... -
Scientific Opinion on a notification (reference C/NL/09/02) for the placing on the market of the genetically modified carnation IFD-26407-2 with a modified colour, for import of cut flowers for ornamental use, under Part C of Directive 2001/18/EC from Florigene
(Journal article; Peer reviewed, 2014)Genetically modified (GM) carnation IFD-26407-2 was developed to express anthocyanins in the petals conferring a mauve colour to the flowers. The GM carnation is intended to be imported in the European Union as cut flower ... -
Scientific Opinion on an application (EFSA-GMO-BE-2011-98) for the placing on the market of herbicide-tolerant genetically modified soybean FG72 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Bayer CropScience
(Journal article; Peer reviewed, 2015)Soybean FG72 was developed by biolistic transformation to express the HPPD W336 and 2mEPSPS proteins, which confer tolerance to isoxaflutole- and glyphosate-based herbicides. The molecular characterisation of soybean FG72 ... -
Scientific Opinion on an application (Reference EFSA-GMO-NL-2011-100) for the placing on the market of the herbicide-tolerant, increased oleic acid genetically modified soybean MON 87705 × MON 89788 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto
(Journal article; Peer reviewed, 2015)The EFSA GMO Panel previously assessed the two single events combined to produce soybean MON 87705 × MON 89788 and did not identify safety concerns. No new data on the single events affecting the previous conclusions were ... -
Scientific Opinion on application (EFSA-GMO-DE-2011-95) for the placing on the market of genetically modified maize 5307 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Syngenta Crop Protection AG
(Journal article; Peer reviewed, 2015)Maize 5307 was developed by Agrobacterium tumefaciens-mediated transformation to express two proteins: eCry3.1Ab, conferring resistance to certain coleopteran pests, and phosphomannose isomerase (PMI), used as selection ... -
Scientific Opinion on application (EFSA-GMO-NL-2010-77) for the placing on the market of herbicide-tolerant genetically modified cotton GHB614 × LLCotton25 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Bayer CropScience
(Peer reviewed; Journal article, 2014)Cotton GHB614 × LLCotton25 was produced by conventional crossing. The EFSA GMO Panel previously assessed the two single cotton events GHB614 and LLCotton25 and did not identify safety concerns. Integrity of ... -
Scientific Opinion on applications (EFSA-GMO-UK-2008-57 and EFSA-GMO-RX-MON15985) for the placing on the market of insect-resistant genetically modified cotton MON 15985 for food and feed uses, import and processing, and for the renewal of authorisation of existing products produced from cotton MON 15985, both under Regulation (EC) No 1829/2003 from Monsanto
(Peer reviewed; Journal article, 2014)Cotton MON 15985 was developed by biolistic transformation of cotton MON 531 to express Cry2Ab2 and GUS in addition to the Cry1Ac and NPTII proteins. Cry proteins in MON 15985 confer resistance ... -
Scientific Opinion on the annual post-market environmental monitoring (PMEM) report from Monsanto Europe S.A. on the cultivation of genetically modified maize MON 810 in 2012
(Peer reviewed; Journal article, 2014)Following a request from the European Commission, the Panel on Genetically Modified Organisms of the European Food Safety Authority (EFSA GMO Panel) assessed the post-market environmental monitoring (PMEM) report for the ... -
Scientific Opinion on the annual post-market environmental monitoring (PMEM) report from Monsanto Europe S.A. on the cultivation of genetically modified maize MON 810 in 2013 from Monsanto Europe S.A.
(Journal article; Peer reviewed, 2015)Following a request from the European Commission, the Panel on Genetically Modified Organisms of the European Food Safety Authority (EFSA GMO Panel) assessed the results of the general surveillance activities contained ... -
Scientific Opinion on the application (EFSA-GMO-BE-2012-110) for the placing on the market of tissue-selective herbicide-tolerant genetically modified maize MON 87427 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto
(Journal article; Peer reviewed, 2015)Maize MON 87427 was developed by Agrobacterium tumefaciens-mediated transformation to express the CP4 5-enolpyruvyl-shikimate-3-phosphate synthase (EPSPS) protein, in all tissues except for the male reproductive tissues, ... -
Screening for frailty among older patients with cancer using blood biomarkers of inflammation
(Peer reviewed; Journal article, 2018)As frailty is associated with inflammation, biomarkers of inflammation may represent objective measures that could facilitate the identification of frailty. Glasgow prognostic score (GPS), combines C-reactive protein (CRP) ... -
Screening for placental dysfunction: The detection of fetal growth restriction and prediction of hypertensive disorders of pregnancy with ultrasound and biochemical markers
(Doctoral thesis at NTNU;2015:152, Doctoral thesis, 2015) -
Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19
(Peer reviewed; Journal article, 2021)Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactives, for activity ...